Introduction {#sec1-1759091419855541}
============

The glutamatergic synapse, referred to as the tripartite synapse, involves three elements: presynaptic neurons, postsynaptic neurons, and astrocytes. There are several different synaptic components expressed on both neurons and astrocytes in the glutamate synapse, as summarized in [Table 1](#table1-1759091419855541){ref-type="table"}. These components include two types of glutamate receptors that exist on these synaptic elements: metabotropic and ionotropic. Metabotropic glutamate receptors (mGluRs) are present on both presynaptic and postsynaptic neurons ([@bibr148-1759091419855541]) and involve three different groups of receptors: Group I (mGluR1 and mGluR5), Group II (mGluR 2 and 3), and Group III (mGluR4, mGluR6, mGluR7, and mGluR8; [@bibr142-1759091419855541]; [@bibr153-1759091419855541]). Group I mGluRs are Gq-coupled and are expressed postsynaptically, depolarizing the postsynaptic neuron upon stimulation ([@bibr142-1759091419855541]; [@bibr48-1759091419855541]; [@bibr148-1759091419855541]). Groups II and III mGluRs are Gi/o-coupled inhibitory autoreceptors and are expressed both pre- and postsynaptically ([@bibr142-1759091419855541]; [@bibr153-1759091419855541]), leading to inhibition of presynaptic glutamate release or postsynaptic excitation ([@bibr4-1759091419855541]; [@bibr48-1759091419855541]).

###### 

Brief Overview of Glutamatergic Synapse Components: Localization and Function.
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  Glutamate synapse components   Localization                   Function                                                                                                                                                                   References
  ------------------------------ ------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  VGluT                          Presynaptic neuron             Packaging glutamate into vesicles                                                                                                                                          [@bibr170-1759091419855541]; [@bibr51-1759091419855541]
  Glutaminase                    Presynaptic neuron             Synthesizes glutamate from glutamine                                                                                                                                       [@bibr148-1759091419855541]
  α7nAChR                        Both neurons and glia          Soluble Aβ binding (in low concentrations) triggers Ca^2+^-dependent release of glutamate from the presynaptic neuron, as well as stimulation of the postsynaptic neuron   [@bibr184-1759091419855541]; [@bibr52-1759091419855541]; [@bibr106-1759091419855541]; [@bibr144-1759091419855541]; [@bibr118-1759091419855541];[@bibr70-1759091419855541]
  mGluR Group II/III             Pre- and postsynaptic neuron   Gi/o-coupled receptor, inhibition of presynaptic release of glutamate or inhibition of postsynaptic response to stimulation                                                [@bibr4-1759091419855541]; [@bibr142-1759091419855541]; [@bibr48-1759091419855541]; [@bibr153-1759091419855541]
  mGluR Group I                  Postsynaptic neuron            Gq-coupled receptor, depolarizes neuron upon binding of glutamate and results in Ca^2+^ release from intracellular stores                                                  [@bibr142-1759091419855541]; [@bibr48-1759091419855541];[@bibr148-1759091419855541]
  AMPA                           Pre- and postsynaptic neuron   Presynaptically promotes the formation of synapses. Postsynaptically depolarizes the neuron upon glutamate binding                                                         [@bibr192-1759091419855541]; [@bibr83-1759091419855541]; [@bibr153-1759091419855541]
  NMDA                           Postsynaptic neuron            Contains a magnesium block that is removed upon depolarization of postsynaptic membrane, allowing for Ca^2+^ influx into the neuron                                        [@bibr24-1759091419855541]; [@bibr192-1759091419855541]; [@bibr134-1759091419855541]; [@bibr140-1759091419855541]; [@bibr153-1759091419855541]
  GLT-1 (EAAT1)/GLAST (EAAT2)    Astrocytes                     Clearance of glutamate from the synapse by uptake into astrocytes                                                                                                          [@bibr100-1759091419855541]; [@bibr148-1759091419855541]
  GS                             Astrocytes                     Conversion of glutamate to glutamine so that it may be transported back to the presynaptic neuron                                                                          [@bibr125-1759091419855541]; Parsons et al., [@bibr140-1759091419855541]; [@bibr148-1759091419855541]

*Note*. Outline of glutamate neuronal and astrocytic components and their functions in glutamatergic neurotransmission.

α7nAChR = alpha-7 nicotinic acetylcholine receptor; AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; EAAT = excitatory amino acid transporter; GLAST = glutamate aspartate transporter; GLT-1 = glutamate transporter-1; GS = glutamine synthetase; mGluR = metabotropic glutamate receptor; NMDA = *N*-methyl-*D*-aspartic acid; VGluT = vesicular glutamate transporter.

The ionotropic glutamate receptors are expressed both pre- and postsynaptically ([@bibr192-1759091419855541]; [@bibr153-1759091419855541]) and include α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR), *N*-methyl-*D*-aspartic acid receptors (NMDAR), and kainate receptors. AMPARs function presynaptically to promote synapse and spine formation ([@bibr83-1759091419855541]). On the postsynaptic side, all three ionotropic receptors are expressed (Wisden and Seeburg, 1993; [@bibr153-1759091419855541]). AMPARs are bound by glutamate and lead to membrane depolarization, while NMDARs have a magnesium block which is released upon membrane depolarization. This results from either high-frequency stimulation inducing Na^+^ influx through AMPARs or disinhibition of GABAergic synapses ([@bibr140-1759091419855541]), which then opens the NMDAR ion channel ([@bibr24-1759091419855541]; [@bibr134-1759091419855541]; [@bibr140-1759091419855541]). In fact, AMPARs and NMDARs are colocalized on the postsynaptic membrane because of the cooperation required between the two receptors in response to membrane depolarization ([@bibr171-1759091419855541]; [@bibr5-1759091419855541]). The opening of NMDARs results in Ca^2+^ influx into the postsynaptic neuron and, along with Group I mGluRs, increases intracellular Ca^2+^ ([@bibr28-1759091419855541]; [@bibr63-1759091419855541]; [@bibr62-1759091419855541]; [@bibr179-1759091419855541]; [@bibr194-1759091419855541]; [@bibr199-1759091419855541]). NMDA interacts with glutamate such that the NR2 subunit of the NMDA receptor binds glutamate, with NR2A and NR2B subtypes mediating excitotoxicity in cultured cortical neurons ([@bibr180-1759091419855541]). The NR2 subunit is expressed both synaptically (NR2A) and extrasynaptically (NR2B; [@bibr153-1759091419855541]). Extrasynaptic NMDARs (E-NMDARS) are activated only by high concentrations of glutamate, unlike synaptic NMDARs (S-NMDARS) that are located closer to the synaptic cleft and are activated by presynaptic glutamate release ([@bibr58-1759091419855541]; [@bibr122-1759091419855541]; [@bibr153-1759091419855541]). Both E-NMDAR stimulation and NMDA/mGluR-mediated Ca^2+^ influx constitute important factors in soluble amyloid beta (Aβ)-mediated neurotoxicity as explored further in this review.

Glutamate is synthesized from glutamine by glutaminase in the presynaptic neuron ([@bibr148-1759091419855541]), and then transported to the synaptic terminals where vesicular glutamate transporter-1/2 (VGluT-1/2) packages glutamate into vesicles, which release glutamate upon neuronal depolarization ([@bibr170-1759091419855541]; [@bibr51-1759091419855541]). Glutamate clearance from the synapse is carried out through high-efficiency excitatory amino acid transporters (EAATs) located primarily on astrocytes. Glutamate transporter-1 (GLT-1) and glutamate aspartate transporter (GLAST) allow for uptake of glutamate into astrocytes ([@bibr100-1759091419855541]), where glutamate is then converted into glutamine by glutamine synthetase (GS) and transported back to the presynaptic neuron ([@bibr125-1759091419855541]). This is referred to as the glutamate/glutamine cycle ([@bibr148-1759091419855541]), a critical regulation point for the glutamatergic system to terminate receptor signaling while preventing excess accumulation of synaptic glutamate potentially leading to excitoxicity ([@bibr130-1759091419855541]). As well, dysregulation of glucose metabolism can potentially impact glutamate synthesis in the glutamate/glutamine cycle ([@bibr90-1759091419855541]), underlining the importance of this regulatory cycle for learning and memory ([@bibr177-1759091419855541]; [@bibr65-1759091419855541]).

Alterations in Glutamatergic Signaling Throughout Alzheimer's Disease Progression {#sec2-1759091419855541}
=================================================================================

The Relationship Between Aβ and Glutamate {#sec3-1759091419855541}
-----------------------------------------

Alzheimer's disease (AD) is characterized by excitotoxic levels of extracellular glutamate alongside accumulation of soluble Aβ and hyperphosphorylated tau protein leading to neuronal cell death ([@bibr75-1759091419855541]; [@bibr93-1759091419855541]). Evidence shows that soluble Aβ accumulation results in synaptic failure, potentially through modifications to the glutamatergic system ([@bibr181-1759091419855541]; [@bibr182-1759091419855541]; [@bibr9-1759091419855541]; [@bibr29-1759091419855541]; [@bibr160-1759091419855541]; [@bibr49-1759091419855541]; [@bibr188-1759091419855541]). Early stages of the disease show an increased excitability of pyramidal neurons ([@bibr59-1759091419855541]; [@bibr165-1759091419855541]; [@bibr69-1759091419855541]) and an upregulation of glutamatergic presynaptic boutons as observed in mild cognitive impairment (MCI; [@bibr12-1759091419855541]) and in mouse models of AD ([@bibr65-1759091419855541]). Several studies have noted hyperactivity in the hippocampus of MCI patients ([@bibr12-1759091419855541]; [@bibr113-1759091419855541]; [@bibr126-1759091419855541]; [@bibr78-1759091419855541]) with familial history of AD ([@bibr127-1759091419855541]) and elevated Aβ deposition ([@bibr78-1759091419855541]) also contributing to excitability. In fact, hyperactivity at baseline, as detected by functional magnetic resonance imaging, is associated with increased severity of cognitive decline ([@bibr113-1759091419855541]; [@bibr126-1759091419855541]; [@bibr78-1759091419855541]).

Along with increased excitability, morphological changes in dendritic structure of hippocampal pyramidal neurons have been noted ([@bibr59-1759091419855541]; [@bibr165-1759091419855541]), with specific responsiveness to amyloid plaques ([@bibr111-1759091419855541]; [@bibr131-1759091419855541]). Whole-cell patch clamp recordings of CA1 pyramidal neurons in AβPP/PS1ΔE9 (APP/PS1; [RRID:MMRRC_034832-JAX](https://scicrunch.org/resolver/RRID:MMRRC_034832-JAX)) mice show reductions in length, branching, and surface area of dendrites while also displaying a localized hyperactivity effect and increased synaptic integration that is attributed to the changes in dendritic structure ([@bibr165-1759091419855541]). Similar morphological changes appear in the PSAPP double transgenic mouse model (Tg2576 [RRID: IMSR_TAC:1349;](https://scicrunch.org/resolver/RRID:IMSR_TAC:1349;) PSEN1 (M146L): [RRID: IMSR_JAX:033255](https://scicrunch.org/resolver/RRID:IMSR_JAX:033255)) and postmortem AD brain samples ([@bibr59-1759091419855541]).

Later stages of AD show markedly decreased glutamatergic activity in stark juxtaposition to earlier hyperactivity. The APP/PS1 AD mouse model shows increased stimulus-evoked glutamate release at younger ages, which then steadily decreases with age and Aβ accumulation ([@bibr114-1759091419855541]; [@bibr69-1759091419855541]; [@bibr67-1759091419855541]). [@bibr21-1759091419855541] also note increased glutamatergic hyperactivity in young APP~swe~/PS1~G384A~ double transgenic mice (APPswe: [RRID: MGI: 3665286](https://scicrunch.org/resolver/RRID:MGI:3665286); PS1~G384A~: [RRID: MGI: 4819108](https://scicrunch.org/resolver/RRID:MGI:4819108)), with hyperactive neurons preferentially surrounding amyloid plaques. Such findings are observed in AD patients, with a decrease in presynaptic glutamatergic boutons and glutamate signaling noted in later disease stages ([@bibr12-1759091419855541]; [@bibr113-1759091419855541]; [@bibr126-1759091419855541]). This could result in chronically elevated glutamate levels eventually leading to inhibition of axonal transport and neurodegeneration through Aβ accumulation and increased Ca^2+^ intracellular concentrations ([@bibr75-1759091419855541]; [@bibr169-1759091419855541]).

Studies attempting to characterize disease cell signaling and pathology in human AD typically use postmortem tissue due to logistical difficulties in obtaining tissues and data from patients in earlier disease stages. Such limitations hinder study of earlier cell signaling changes, although there are some methods currently used to examine glutamate in live patients. Of note, studies using proton magnetic resonance spectroscopy (1H MRS) and glutamate chemical exchange saturation transfer (GluCEST) show decreased overall glutamate concentration in APP/PS1 mice and AD patients ([@bibr154-1759091419855541]; [@bibr64-1759091419855541]). The hippocampus was specifically noted as having a large decrease in glutamate concentration, and as previously discussed, the hippocampus is especially vulnerable to Aβ accumulation. The CA1 region is particularly susceptible to disease-related neuronal loss ([@bibr187-1759091419855541]; [@bibr77-1759091419855541]) and shows decreased stimulus-evoked glutamate with age in APP/PS1 mice ([@bibr68-1759091419855541]). This supports that the decrease in total concentration observed may be a consequence of neuronal loss resulting from excitotoxicity, as opposed to decreased glutamate concentration in the hippocampus.

These findings display a flexibility in glutamatergic characterization such that it is specific to the disease stage. The paradoxical nature of glutamate signaling in AD petitions for a deeper look into the individual impact on glutamatergic synaptic components throughout disease progression. Modifications in expression of synaptic elements could lead to alterations in cell signaling, allowing for excitotoxic conditions to grow and building the foundation for cognitive decline.

Neuronal Glutamate Synaptic Component Changes in AD {#sec4-1759091419855541}
---------------------------------------------------

Individual changes in glutamatergic synaptic components underlie the altered glutamate release observed throughout disease progression. As mentioned previously, earlier stages are marked with elevated glutamate release that eventually increases glutamate concentrations in and around the synapse. Evidence supports that this starts presynaptically, with Aβ and VGluT1 colocalizing on glutamatergic synaptic boutons and preferentially accumulating in these terminals ([@bibr167-1759091419855541]). This coincides with elevated expression of VGluT1 in mouse models of AD, supporting increased vesicle trafficking of glutamate (Hascup et al., 2019a). Several studies have also shown a downregulation of VGluT1 expression in [@bibr86-1759091419855541]; Canas et al., 2014; Rodriguez-Perdigon et al., 2016), but only VGluT2 downregulation in MCI subjects ([@bibr86-1759091419855541]), supporting that VGluT1 levels are not downregulated until later stages of AD. This expression pattern matches that of glutamate release such that initially more glutamate is packaged into vesicles for release, contributing to an increase in extracellular glutamate levels into a toxic range.

Postsynaptically, the impact of Aβ accumulation on AMPA/NMDA receptors has been well documented. Bath application of Aβ reduces both the amplitude and frequency of AMPA postsynaptic currents in CA1 pyramidal neurons ([@bibr135-1759091419855541]). Neuronal cell cultures taken from the cortex and hippocampus of Tg2576 transgenic AD mice show decreased expression of the GluR1 AMPA subunit as Aβ concentrations increased (Almedia et al., 2005). A decrease in GluR1 and GluR2/3 expression has also been observed in postmortem AD entorhinal cortex ([@bibr195-1759091419855541]), although GluR2/3 is expressed presynaptically as well. In the hippocampus, ionotropic glutamate receptor AMPA subunit-4 expression is downregulated in sporadic AD ([@bibr84-1759091419855541]), along with decreased AMPA binding in the CA1 ([@bibr40-1759091419855541]). It is arguable that the decrease in AMPA binding may be due to decreased GluR1 surface expression caused by decreased expression of synaptic calcium-calmodulin II (CaMKII) as seen in APP/PS1 mice ([@bibr60-1759091419855541]). The decreased release of stimulus-evoked glutamate mentioned earlier could also account for this decrease in binding ([@bibr69-1759091419855541]). In cell culture, GluA1 expression is upregulated in APP knockout corticohippocampal neurons supporting that Aβ directly impacts expression levels of AMPA subunits ([@bibr110-1759091419855541]). Interestingly, GluR2 has been shown to be upregulated in incipient AD patients (Williams et al., 2009), supporting that AMPA expression may follow the same cycle of early upregulation and then subsequent downregulation with AD progression. Early upregulation is likely a response to increased presynaptic glutamate stimulation, but overtime, chronic excessive stimulation leads to desensitization and internalization of the AMPA receptor ([@bibr46-1759091419855541]).

NMDA receptors are a cornerstone in the relationship between Aβ accumulation and glutamate toxicity. Aβ~42~ preferentially binds to glutamatergic neurons expressing NR1 or NR2B NMDA subunits compared with other subunits ([@bibr95-1759091419855541]). Aβ~42~ can stimulate glutamate release, potentially through α7 nicotinic acetylcholine receptors (α7nAChR; discussed later), to activate E-NMDARs ([@bibr172-1759091419855541]). This can result in long-term potentiation (LTP) inhibition ([@bibr102-1759091419855541]; [@bibr88-1759091419855541]) and contribute to synaptic spine loss ([@bibr172-1759091419855541]). This Aβ-mediated increase in glutamate concentration leads to endocytosis and decreased surface expression of NR1 and NR2B ([@bibr166-1759091419855541]). Downregulated NMDA subunit expression in the hippocampus has been observed in several postmortem studies in human AD subjects ([@bibr80-1759091419855541]; [@bibr84-1759091419855541]).

NMDARs are believed to mediate soluble Aβ-induced cell death such that persistent activation of NMDA from excessive glutamate release leads to selective neuronal death from chronic excitotoxicity ([@bibr23-1759091419855541]). E-NMDARs allow for Ca^2+^ entry into the cell ([@bibr199-1759091419855541]), which causes increased dendritic calcium-induced calcium release from ryanodine receptors, thus increasing intracellular Ca^2+^ concentrations ([@bibr55-1759091419855541]). In fact, MCI patients show increased expression of ryanodine receptor 2 ([@bibr18-1759091419855541]), which would allow for further NMDA-mediated increases in intracellular Ca^2+^ concentrations. Overtime, this can eventually result in toxic Ca^2+^ levels leading to depolarization of the mitochondrial membrane, free radical production, and cell death. ([@bibr63-1759091419855541]; [@bibr62-1759091419855541]; [@bibr13-1759091419855541]; [@bibr199-1759091419855541]). Along with this, E-NMDAR-mediated Ca^2+^ influx activates cAMP-regulatory element binding protein (CREB) shut off pathways ([@bibr63-1759091419855541]). CREB plays a central role in long-term memory ([@bibr196-1759091419855541]; [@bibr8-1759091419855541]; [@bibr174-1759091419855541]), and downregulation results in memory impairment ([@bibr193-1759091419855541]; [@bibr198-1759091419855541]). Thus, increased intracellular Ca^2+^ levels resulting from E-NMDAR stimulation contributes to both cognitive decline and neuronal loss in AD pathology.

Furthermore, soluble Aβ acts through NMDAR to activate nicotinamide adenine dinucleotide phosphate oxidase leading to induction of reactive oxygen species (ROS; [@bibr89-1759091419855541]) and release of arachidonic acid ([@bibr163-1759091419855541]). The influx of Ca^2+^ from NMDAR activation is required for ROS formation ([@bibr36-1759091419855541]). Although NMDA production of ROS is a necessary element for LTP ([@bibr89-1759091419855541]), Aβ stimulates an excessive ROS induction from NMDARs, leading to oxidative damage and synaptic failure ([@bibr36-1759091419855541]; [@bibr163-1759091419855541]). In fact, elevated ROS levels contribute to impairment of LTP ([@bibr161-1759091419855541]) and spatial learning ([@bibr124-1759091419855541]) with age. NMDA activation also increases nitric oxide (NO) synthesis ([@bibr53-1759091419855541]) in a Ca^2+^ ([@bibr97-1759091419855541]) and postsynaptic density-95 dependent manner ([@bibr155-1759091419855541]). The 3xTg-AD ([RRID: MMRRC_034830-JAX](https://scicrunch.org/resolver/RRID:MMRRC_034830-JAX)) mouse model shows significant increases in NMDA-mediated NO concentration peaks in the CA1 at earlier disease stages, which then substantially decreased with age ([@bibr41-1759091419855541]), an effect that could underlie the changes in glutamate cell signaling seen throughout disease progression. Furthermore, inducible nitric oxide synthase (iNOS) mediates Aβ-induced LTP inhibition (Wang et al., 2004), while soluble Aβ works through both NMDA and NOS to increase oxidative stress ([@bibr136-1759091419855541]). However, NO can in turn inhibit NMDAR action ([@bibr107-1759091419855541]), which could play a role in decreased NMDAR activity in later stages of AD. Even with increasing neurotoxicity, NOS+ neurons in the hippocampus are relatively spared ([@bibr79-1759091419855541]), supporting a complicated relationship between NO and glutamate such that NO provides some neuroprotection while also contributing to the consequences of excitotoxicity.

Studies performed in primary cortical neuron cultures have shown seemingly opposing results on NMDA modulation of APP processing. NMDA (50 µM) treatment showed both induction of Kunitz protease inhibitory domain (KPI)-APP neuronal expression promoting production of Aβ~42~ ([@bibr101-1759091419855541]), and increases in α-carboxyterminal fragment levels, supporting enhancement of nonamyloidogenic α-secretase cleavage ([@bibr76-1759091419855541]). Interestingly, the increase in α-carboxyterminal fragment levels was not observed in isolated E-NMDARs, supporting that this is solely an S-NMDAR effect ([@bibr76-1759091419855541]). Furthermore, [@bibr101-1759091419855541] used a longer NMDA incubation period (24 hr) to create an excitotoxic environment, as would be observed with chronic E-NMDAR stimulation. [@bibr16-1759091419855541] addressed these conflicting findings by isolating either S-NMDARs or E-NMDARs in primary cortical neuron culture. While S-NMDARs were shown to have no impact on KPI-APP neuronal expression, E-NMDARs increased KPI-APP expression at the 12- and 24-hr time points. This E-NMDAR-mediated increase in KPI-APP expression was also found to be calcium-calmodulin dependent, supporting induction through NMDA-mediated Ca^2+^ entry into the neuron. Along with these findings, NMDA antagonists are capable of blocking Aβ~42~ uptake into hippocampal neurons (Bi et al., 2002) where Aβ can reduce axonal transport through an NMDA/glycogen synthase kinase-3β dependent mechanism ([@bibr37-1759091419855541]). This further emphasizes the critical roles of E-NMDARs in AD, impacting both APP processing and Aβ~42~ internalization, and thereby establishing E-NMDARs as a central mediator to the neurotoxic effects of Aβ.

Autoradiography studies of postmortem brain tissue shows decreased binding to mGluRs and decreased mGluR/neuronal density ratio ([@bibr40-1759091419855541]; [@bibr3-1759091419855541]). This effect was associated with a decrease in mGluR1 expression, which continuously declines with AD progression ([@bibr3-1759091419855541]). Interestingly, another study found mGluR2, which is primarily expressed presynaptically, to be upregulated in AD ([@bibr98-1759091419855541]). mGluR2 protects against excitotoxicity by inhibiting presynaptic glutamate release ([@bibr20-1759091419855541]; [@bibr82-1759091419855541]; [@bibr66-1759091419855541]; [@bibr145-1759091419855541]; [@bibr67-1759091419855541]) and has been shown to directly activate extracellular signal-regulated kinase (ERK) in a phosphoinositide 3-kinase (P13K)-dependent manner ([@bibr47-1759091419855541]). ERK impacts CREB phosphorylation and promotes cell survival ([@bibr105-1759091419855541]; [@bibr99-1759091419855541]) but also phosphorylates tau which can contribute to aberrant hyperphosphorylation resulting in neurofibrillary tangles ([@bibr99-1759091419855541]). These findings support that while this mechanism may initially be neuroprotective ([@bibr15-1759091419855541]), over time, it may contribute to disease pathology.

Astrocytic Glutamate Component Changes in AD {#sec5-1759091419855541}
--------------------------------------------

Astrocytes play a key role both in the tripartite glutamatergic synapse and in AD pathogenesis ([@bibr153-1759091419855541]). Reactive astrocytes are known to associate with senile plaques in AD mouse models and human tissue (Verkhratsky et al., 2010; [@bibr151-1759091419855541]), leading to astrogliosis in the hippocampus and cortex characterized by increased expression of glial fibrillary acidic protein (GFAP; [@bibr120-1759091419855541]; [@bibr128-1759091419855541]; [@bibr65-1759091419855541]). This response is triggered by damaged neuronal signals, referred to as damaged-associated molecular patterns, and Aβ plaque deposition (Verkhratsky et al., 2010) leading to increased release of proinflammatory factors such as interleukin-1β (IL-1β) and tumor necrosis factor-α ([@bibr117-1759091419855541]). Continuing induction of astrocytic response leads to chronic inflammation that results in cell damage ([@bibr168-1759091419855541]).

Glutamate clearance from the synapse is hindered in AD through decreased uptake into astrocytes. This is supported by decreased expression of both GLT-1 and GLAST in the hippocampus ([@bibr25-1759091419855541]) that appears prior to plaque deposition ([@bibr156-1759091419855541]). In later stages, GLT-1 expression is markedly decreased around plaques ([@bibr71-1759091419855541]). Expression of GLT-1 may be directly impacted by Aβ through lipid peroxidation and 4-hydroxynonenal modification as a result of oxidative stress ([@bibr22-1759091419855541]). This change in GLT-1 expression contributed to spatial learning deficits in earlier stages (6 months old) but did not cause a significant deviation in cognitive performance in 9-month-old APP/PS1 mice lacking one GLT-1 allele ([@bibr116-1759091419855541]). This effect is also observed with decreased expression of EAAT-2 (the human GLT-1 equivalent) in postmortem AD cortex ([@bibr158-1759091419855541]) as well as EAAT-1 (GLAST) reduction in the hippocampus ([@bibr84-1759091419855541]). Again, this reduction was specifically noted in the vicinity of senile plaques ([@bibr84-1759091419855541]; [@bibr71-1759091419855541]), supporting elevated basal glutamate surrounding plaques in both mouse and human models. Interestingly, several disease-specific splice variants of EAAT2 exist that reduce the glutamate transport capacity of EAAT2 in AD postmortem tissue ([@bibr158-1759091419855541]). This may offer an additional avenue for excitoxicity, whereby glutamate transporters are both downregulated and have decreased functional glutamate clearance.

GS action upon glutamate is a critical component in preventing excitotoxicity ([@bibr179-1759091419855541]; [@bibr153-1759091419855541]) but shows altered expression in AD ([@bibr150-1759091419855541]; [@bibr17-1759091419855541]; [@bibr129-1759091419855541]; [@bibr132-1759091419855541]; Huang et al., 2016). In 3xTg-AD mice, GS+ astrocyte distribution mirrored that of GFAP+ distribution in the DG and CA1, but by 12 months of age, GS+ astrocyte cell counts decreased, and by 18 months of age, downregulation of GS expression in the hippocampus was observed ([@bibr129-1759091419855541]). Human tissue taken from patients with advanced AD also shows a decrease in GS expression. Interestingly, less GS staining was observed clustering around plaques, unlike GFAP+ astrocytes ([@bibr150-1759091419855541]). This is possibly due to the level of neuronal loss experienced during advanced stages of AD ([@bibr38-1759091419855541]; [@bibr159-1759091419855541]). GS is particularly vulnerable to oxidative modification ([@bibr17-1759091419855541]) that makes it a potential target of Aβ-induced oxidative damage (Huang et al., 2016). Along with this, GS inhibition in activated microglia results in stronger induction of inflammatory markers which increases neuronal toxicity ([@bibr132-1759091419855541]).

The evidence presented for both neuronal and astrocytic components of the tripartite glutamate synapse involvement in AD progression support that Aβ can impact the glutamatergic system through various mechanisms. Changes in expression of each of the synaptic components lead to chronically elevated extracellular glutamate that becomes excitotoxic and underlies AD pathology.

Aβ--α7nAChR Interactions {#sec6-1759091419855541}
========================

α7nAChRs are expressed on both neurons and glia, with hippocampal immunostaining showing the highest density of α7nAChR-expressing neurons in the neuropil and α7nAChR-expressing glia in the distal regions of the stratum radiatum ([@bibr52-1759091419855541]). It has been well established in the literature that application of nicotine elicits glutamate release both *in vitro* and *in vivo* ([@bibr108-1759091419855541]; [@bibr96-1759091419855541]; [@bibr92-1759091419855541]). *In vivo* microelectrode array recording studies have shown nicotine-induced glutamate release in the prefrontal cortex of freely moving rats, that is attenuated with application of α-bungarotoxin, an α7nAChR antagonist ([@bibr92-1759091419855541]). Soluble Aβ~40~ and Aβ~42~ interact with nAChRs at these synapses ([@bibr183-1759091419855541]) impacting glutamate release. Aβ interacts with both α7 and α4β2 nAChRs; however, α4β2nAChR receptor binding requires a significantly higher concentration than α7nAChR ([@bibr184-1759091419855541]). Regarding differences between Aβ~40~ and Aβ~42~, Aβ~40~ was found to bind with less affinity and decreased potency compared with Aβ~42~ ([@bibr183-1759091419855541]; [@bibr42-1759091419855541]). More specifically, Aβ~42~ binds with femtomolar affinity to the nicotine/acetylcholine (ACh)-binding pocket of α7nAChR ([@bibr184-1759091419855541]; [@bibr106-1759091419855541]) and can elicit different responses dependent on Aβ preparation and concentration used ([@bibr137-1759091419855541]; [@bibr70-1759091419855541]). High concentrations of Aβ (nM-µM) noncompetitively block hippocampal α7nAChRs in *in vitro* hippocampal cell culture and slices ([@bibr104-1759091419855541]; [@bibr118-1759091419855541]). Alternatively, low concentrations of Aβ (fM-pM) have been shown to potentiate glutamate release ([@bibr144-1759091419855541]; [@bibr118-1759091419855541]; [@bibr70-1759091419855541]) with some effects on aspartate and GABA release also observed *in vivo* ([@bibr118-1759091419855541]). In fact, Aβ-stimulated α7nAChR glutamate release from neurons and astrocytes can result in rising extracellular glutamate levels that can chronically activate E-NMDARs, thereby contributing to excitotoxicity ([@bibr153-1759091419855541]).

Lower concentrations of Aβ~42~ have been shown to enhance LTP and spatial memory performance in C57BL/6 mice ([RRID: IMSR_JAX:000664](https://scicrunch.org/resolver/RRID:IMSR_JAX:000664); [@bibr144-1759091419855541]), while higher concentrations result in LTP deficits ([@bibr27-1759091419855541]; [@bibr61-1759091419855541]). The LTP-enhancing aspect of Aβ~42~ is not mediated by AMPA/NMDA receptors, as Aβ~42~ perfusion of hippocampal slices does not impact AMPA/NMDA receptor currents or amplitude frequency and distribution ([@bibr144-1759091419855541]). This concentration-dependent action of Aβ supports a transformation from excitation to inhibition of α7nAChRs as AD progresses, with Aβ levels rising from picomolar to nanomolar levels ([@bibr121-1759091419855541]; [@bibr6-1759091419855541]; Puzzo and Arancio, 2012). It should be noted that presynaptic α7nAChRs are known to interact with neighboring NMDARs such that the chronic inactivation of α7nAChR, resulting from desensitization by Aβ, could result in enhanced NMDAR function ([@bibr103-1759091419855541]). However, this increased presynaptic glutamate release may not evoke LTP enhancement as postsynaptic AMPA/NMDA receptors become desensitized and downregulated in the excitotoxic state associated with AD ([@bibr195-1759091419855541]; [@bibr159-1759091419855541]; [@bibr80-1759091419855541]; [@bibr135-1759091419855541]).

Evidence of Aβ~42~ concentration-dependent α7nAChR modulation is further characterized through microelectrode array recordings in the hippocampus. [@bibr70-1759091419855541] showed glutamatergic stimulation with local application of Aβ~42~ in hippocampal recordings from anesthetized C57BL/6 mice, an effect that was blocked with co-application of α-bungarotoxin supporting involvement of α7nAChR. Interestingly, different responses to Aβ~42~ application were observed depending on the hippocampal subfield, with the CA1 and dentate gyrus responding most to lower concentrations of Aβ~42~ compared with the CA3. These findings mirror current knowledge of AD disease progression, with the CA1 showing the earliest increases in glutamate release in the APP/PS1 transgenic AD mouse model ([@bibr69-1759091419855541]) and the earliest site of plaque deposition for the hippocampus in human AD patients ([@bibr173-1759091419855541]; [@bibr164-1759091419855541]).

α7nAChRs open upon nicotine binding, allowing a Ca^2+^ influx into the presynaptic neuron ([@bibr57-1759091419855541]). Similarly, binding of soluble Aβ to the α7nAChR triggers an influx of Ca^2+^ into the presynaptic neuron ([@bibr43-1759091419855541]; [@bibr45-1759091419855541]) and has been shown to activate the ERK/mitogen-activated protein kinases pathway ([@bibr43-1759091419855541]; [@bibr11-1759091419855541]; [@bibr1-1759091419855541]; [@bibr197-1759091419855541]) in a P13K-dependent manner ([@bibr11-1759091419855541]) which in turn impacts the phosphorylation of CREB ([@bibr43-1759091419855541]). Intraperitoneal injection of α7nAChR selective agonist A-582941 resulted in increased ERK 1/2 and CREB phosphorylation that improved behavioral performance on delayed matching to sample titration, inhibitory avoidance, and social recognition ([@bibr14-1759091419855541]). However, in the Tg2576 mouse model, CREB was found to be upregulated at 13 months of age and then downregulated by 20 months of age ([@bibr43-1759091419855541]). This supports that CREB activation mirrors the Aβ-α7nAChR interaction such that CREB expression is enhanced in the early stages of AD when there are lower concentrations of Aβ, and then decreases with disease progression corresponding to Aβ accumulation.

The potentiation of glutamate release from Aβ activation of α7nAChR contributes to excitotoxicity while also resulting in rapid desensitization of the α7nAChR ([@bibr44-1759091419855541]). Aβ~42~ and α7nAChR have been shown to form a complex that becomes internalized in the neuron and leads to cell lysis and plaque deposition ([@bibr33-1759091419855541]; [@bibr119-1759091419855541]; [@bibr39-1759091419855541]; [@bibr54-1759091419855541]). In fact, Aβ accumulates at a faster rate in neuroblastoma cells transfected with α7nAChR (Nagele et al., 2002). The Aβ~42~-α7nAChR complex internalization leads to decreased surface expression of α7nAChR (Nagele et al., 2002), coinciding with upregulation of α7nAChR seen throughout AD progression ([@bibr72-1759091419855541]; [@bibr43-1759091419855541]; [@bibr32-1759091419855541]) supporting an α7nAChR compensatory mechanism for decreased surface expression. Interestingly, this chronic desensitization of α7nAChR has been shown to increase NMDAR surface expression ([@bibr103-1759091419855541]), suggesting a complex compensatory response to accumulation of Aβ~42~.

Learning and Memory Consequences of Altered Glutamatergic Signaling {#sec7-1759091419855541}
===================================================================

Glutamatergic dysfunction due to deregulation of synaptic components has phenotypic consequences in the form of decreased learning and memory performance. Presynaptically, reductions in VGluT1 and VGluT2 correlated with decline in cognitive status and disease duration in AD patients ([@bibr86-1759091419855541]). Cognitive ability is negatively correlated with glutamate presynaptic bouton density in MCI patients such that the increase in bouton density leads to decreased cognitive ability ([@bibr12-1759091419855541]). Similarly, elevated hippocampal glutamate release negatively correlated with cognitive performance prior to cognitive decline in APP/PS1 mice ([@bibr69-1759091419855541]). This is in stark contrast to cognitively normal patients that have a positive correlation ([@bibr12-1759091419855541]), supporting a threshold in which increased glutamate signaling switches from stimulating to hindering cognition.

NMDA and mGluRs are both known to play vital roles in induction of LTP and long-term depression (LTD; Parameshwaran et al., 2007; [@bibr162-1759091419855541]). Soluble Aβ inhibits S-NMDARs that are required for LTP conduction ([@bibr31-1759091419855541]; [@bibr140-1759091419855541]). Treatment with (2*R*)-amino-5-phosphonovaleric acid (D-AP5), a selective NMDA antagonist, impairs LTP *in vivo* supporting that the involvement of NMDARs in LTP ([@bibr35-1759091419855541]). However, in GLT-1 knockout mice, the LTP impairment observed was reversed with application of D-AP5, supporting that both blockade and overactivation of NMDARs can interfere with LTP ([@bibr87-1759091419855541]). This effect may be due to the involvement of E-NMDARs, whereby inhibition of E-NMDARs prevents Aβ-mediated LTP impairments ([@bibr102-1759091419855541]; [@bibr146-1759091419855541]). Memantine, an FDA-approved noncompetitive NR2 antagonist ([@bibr139-1759091419855541]) for treating AD has shown efficacy in improving Morris water maze performance ([@bibr10-1759091419855541]; [@bibr178-1759091419855541]; [@bibr7-1759091419855541]) and blocked Aβ inhibition of LTP in 3xTg-AD hippocampal slices ([@bibr138-1759091419855541]; [@bibr109-1759091419855541]). Thus, supporting that noncompetitive inhibition of NR2+ NMDARs provides a counterbalance to both inhibition of S-NMDARS and overactivation of E-NMDARS, explored further in the next section.mGluRs are involved in both the Aβ-induced suppression of LTP and potentiation of LTD (Wang et al., 2004; [@bibr162-1759091419855541]; [@bibr146-1759091419855541]). Aβ-mediated LTP impairments can be blocked by inhibition of mGluR5 (Wang et al., 2004; [@bibr146-1759091419855541]). As NMDARs and mGluRs are mechanistically coupled, chronic stimulation of either can lead to synaptic failure as seen in AD ([@bibr146-1759091419855541]; [@bibr88-1759091419855541]). This failure is potentially due to Ca^2+^ dysregulation and dephosphorylation of CREB as both E-NMDARs and mGluR5 elevate intracellular Ca^2+^ ([@bibr28-1759091419855541]; [@bibr63-1759091419855541]; [@bibr62-1759091419855541]; [@bibr179-1759091419855541]; [@bibr194-1759091419855541]; [@bibr199-1759091419855541]). In addition, mGluR1 has been shown to be involved in synaptic plasticity and LTP in the CA1 ([@bibr123-1759091419855541]; [@bibr153-1759091419855541]). Of note, agonism of mGluR1 and mGluR5 with 3-hydroxyphenylglycine potentiated NMDAR-induced neurotoxicity, juxtaposing the neuroprotective effects observed with mGluR2 agonism ([@bibr20-1759091419855541]; Tyszkiewicz and Yan, 2005) and further supporting a deleterious relationship between NMDAR and mGluRs upon LTP and excitotoxicity. Furthermore, mGluRs are required for soluble Aβ-mediated LTD enhancement ([@bibr162-1759091419855541]; [@bibr133-1759091419855541]; [@bibr176-1759091419855541]). Treatment with a similar Group I mGluR agonist, 3,5-dihydroxyphenylglycine, results in decreased AMPAR surface expression during LTD ([@bibr176-1759091419855541]), supporting another mechanism by which soluble Aβ impacts learning and memory signal conductance.

Theories on the Paradoxical Nature of Glutamate in AD {#sec8-1759091419855541}
=====================================================

The two-stage model theory was first set forth by [@bibr130-1759091419855541] describing two stages of NMDAR-mediated toxicity in AD pathology. The first stage, referred to as NRHyper, describes persistent activation of NMDA receptors. Chronic NMDAR stimulation then leads to the second disease stage, referred to as NRHypo, in which the NMDARs become hypoactive as a result of chronic overstimulation leading to inhibition of LTP conductance and cognitive decline. These disease stages are driven by soluble Aβ accumulation. During the NRHyper phase, Aβ potentiates glutamate release and increases NMDA activation and sensitivity to glutamate. This leads to partial membrane depolarization allowing tonic activation of NMDA receptors ([@bibr91-1759091419855541]; [@bibr56-1759091419855541]; [@bibr34-1759091419855541]). This overstimulation subsequently results in an NRHypo state in which glutamatergic activation is depressed and synaptic components are downregulated. NMDARs become hypofunctional in normal brain aging; however, this is experienced to an extreme in AD possibly due to the increase hyperactivation state experienced in AD that precedes hypoactivation. NMDAR hypoactivation applies to NMDARs on GABAergic neurons as well, causing disinhibition of the glutamatergic system and resulting in increased extracellular glutamate concentrations and neuronal loss. This is expanded upon by the findings of Huijber et al. (2015) and the trait versus state hypothesis set forth by [@bibr2-1759091419855541], describing two models of hippocampal activity such that some individuals have a *trait* of high levels of hippocampal activation prior to MCI and some experience hyperactivation as a *state* with MCI onset. Both models subsequently result in cognitive decline and support a period of hippocampal hyperactivation occurring before hypoactivation.

Similarly, [@bibr140-1759091419855541] proposed the signal-to-noise ratio hypothesis. This hypothesis notes that in AD pathology, NMDAR is stimulated by glutamate for longer periods of time due to a hyperactive glutamatergic system ([@bibr19-1759091419855541]; [@bibr115-1759091419855541]). As such, this leads to tonic activation of NMDAR that generates increasing amounts of *noise*. This noise raises the threshold by which neuronal stimulation must pass to generate a stimulus-evoked *signal*. With disease progression, the increased noise eventually drowns out the signal, leading to learning and memory deficits seen in AD. This effect has been observed in our lab, with APP/PS1 mice showing a decline in stimulus-evoked glutamate and an increase in basal glutamate levels with disease progression, impacting spatial memory performance ([@bibr69-1759091419855541]). This hypothesis is further elucidated with the proposed action of memantine, the noncompetitive NR2 antagonist, which shows fast unblocking kinetics dependent upon membrane potential. This characteristic allows memantine to quickly unblock the NMDAR during strong depolarization of the postsynaptic membrane and remain bound during tonic stimulation. In fact, recovery from memantine blockade is shown to be even faster in the presence of higher synaptic glutamate concentrations ([@bibr30-1759091419855541]). Memantine benefits both S-NMDARs and E-NMDARs in LTP such that LTP conductance is not hindered at the synapse but chronic stimulation of E-NMDARs is blocked, ultimately helping to alleviate excitotoxic effects. This is seen with memantine improvements in LTP induction and Morris water maze performance as discussed earlier ([@bibr10-1759091419855541]; [@bibr178-1759091419855541]; [@bibr7-1759091419855541]; [@bibr138-1759091419855541]; [@bibr109-1759091419855541]). Of note, memantine has also showed efficacy in reducing Aβ production brought on by E-NMDAR prolonged activation ([@bibr16-1759091419855541]), as well as reducing the levels of both soluble Aβ and insoluble Aβ plaques in 3xTg-AD mice ([@bibr109-1759091419855541]) and blocking soluble Aβ-induced oxidative stress ([@bibr36-1759091419855541]). As such, memantine shows modulation of Aβ-and-glutamate-induced neurotoxicity giving support to the idea that noise created by extracellular glutamate overpowers stimulus-evoked glutamate signals in AD.

In clinical trials, memantine was shown to reduce cognitive deficits in mild to severe AD patients ([@bibr191-1759091419855541]; [@bibr147-1759091419855541]; [@bibr141-1759091419855541]). A meta-analysis of memantine trials also revealed efficacy in treating patients with moderate to severe AD ([@bibr190-1759091419855541]). However, the weak procognitive effects observed in AD patients treated with memantine ([@bibr112-1759091419855541]; [@bibr157-1759091419855541]) may be due to the disease stage when treatment was initiated. If memantine treatment is initiated too late in disease progression, neuronal loss may be too severe to yield procognitive effects. As such, post hoc analysis of nine clinical trials of memantine show delay of clinical worsening in moderate to severe AD patients ([@bibr73-1759091419855541]). Danysz and Parsons (2012) argue that starting treatment in the prodromal stage of AD would allow for memantine-induced neuroprotection, which could yield more promising clinical results and further delay cognitive decline.

In addition, NMDARs are not the only components that modulate the signal-to-noise ratio. mGluRs are multifaceted due to their G-protein and NMDAR coupling and as such are also a vital mediator in LTP. [@bibr149-1759091419855541] has argued that mGluRs are responsible for the initial setup of the signal-to-noise ratio to allow for efficient plasticity. Pretraining injection of mGluR agonists leads to nonspecific activation of Group I mGluRs, generating an increase in noise and preventing memory formation. Groups II and III mGluRs then act as mediators to reduce noise and allow for signal conductance and memory formation. This initial organization of the signal-to-noise ratio is impacted at the mGluR level in AD pathology, as mentioned earlier with mGluR1 and mGluR5 potentiating NMDA-induced neurotoxicity and then experiencing a downregulation in expression in later disease stages ([@bibr20-1759091419855541]; [@bibr3-1759091419855541]), following a similar hyper- to hypoactivation trend. This initial noise generation overpowers the inhibitory modulation of mGluR2, despite its upregulation in early AD ([@bibr20-1759091419855541]). However, our laboratory recently demonstrated that prodromal treatment with the mGluR Group II agonist LY379268 does not offer long-term procognitive benefits in APP/PS1 mice ([@bibr67-1759091419855541]).

Furthermore, our laboratory and others have reported a relationship between Aβ and glutamate mediated by α7nAChR stimulation that contributes to increases in glutamate release ([@bibr144-1759091419855541]; [@bibr118-1759091419855541]; [@bibr70-1759091419855541]), generating a large amount of signal. This relationship changes as AD progresses and Aβ increases in concentration and plaque formation such that we see an opposite impact through α7nAChR in which glutamate release is inhibited and thus contributes to overall hypoactivation ([@bibr104-1759091419855541]; [@bibr118-1759091419855541]). Interestingly, α7nAChR desensitization leads to increased NMDAR surface expression and enhanced function ([@bibr103-1759091419855541]), and both pathways modulate Aβ toxicity such that α7nAChR and E-NMDARs lead to Aβ~42~ internalization ([@bibr33-1759091419855541]; Bi et al., 2002; [@bibr119-1759091419855541]; [@bibr39-1759091419855541]; [@bibr54-1759091419855541]), and E-NMDARs lead to increased amyloidogenic processing ([@bibr16-1759091419855541]). In addition, nicotine-mediated enhancement of LTP is both NMDA and mGluR5 dependent ([@bibr186-1759091419855541]), and because Aβ~42~ binds to the same pocket as nicotine, it follows that mGluR5 may potentiate both NMDA and α7nAChR-induced excitotoxicity. Other pathways previously discussed in this review also result in toxic Ca^2+^ intracellular levels and modulation in CREB expression that result in neuronal cell loss. This interaction between multiple glutamatergic pathways emphasizes the breadth of Aβ modulation of the glutamatergic system to generate neurotoxicity as outlined in [Figure 1](#fig1-1759091419855541){ref-type="fig"}.

![Changes in glutamatergic synapse component expression and signaling with AD progression. (a) Preclinical AD upregulation of several neuronal components contributing to hyperactivation and building the foundation for excitotoxicity. (b) Clinical AD is characterized by hypoactivation of the glutamatergic system, possibly a consequence of the earlier preclinical stage. This results in cognitive deficits due to signal-to-noise ratio imbalance.\
AD = Alzheimer's disease; α7nAChR = alpha-7 nicotinic acetylcholine receptor; Aβ~o~ = amyloid beta oligomer; VGluT1 = vesicular glutamate transporter 1; AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; E-NMDAR = extrasynaptic *N*-methyl-*D*-aspartic acid receptor; mGluR = metabotropic glutamate receptor; S-NMDAR = synaptic *N*-methyl-*D*-aspartic acid receptor; EAAT = excitatory amino acid transporter.](10.1177_1759091419855541-fig1){#fig1-1759091419855541}

Conclusion {#sec9-1759091419855541}
==========

Taken together, the presented evidence supports a signal-to-noise ratio imbalance occurring in AD pathology. Aβ modulates several parts of the tripartite glutamatergic synapse that culminates in an excitotoxic environment. The excitation threshold at which glutamate signals must surpass for learning and memory increases while also undergoing an overall dampening of the glutamatergic system. Loss of signal detection due to persistently elevated synaptic and extrasynaptic glutamate levels leads to the hallmark symptoms of cognitive deficits and eventual neuronal loss in AD disease progression.

Summary {#sec10-1759091419855541}
=======

Glutamatergic transmission displays stark changes throughout AD progression. Earlier stages are characterized by upregulation of synaptic components contributing to increased glutamate signaling. Later stages exhibit hypoactivation possibly due to cell damage and neuronal loss, subsequently resulting in cognitive decline.
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